On August 31, 2017 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, reported the presentation of a trial-in-progress poster describing preliminary clinical data from the dose escalation stage of CA-170 Phase 1 clinical trial at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2017 Congress (Press release, Curis, AUG 31, 2017, View Source [SID1234520345]). The conference will take place September 8-12 in Madrid. CA-170, an oral small molecule targeting the immune checkpoints PDL1 and VISTA, is in development for the treatment of patients with advanced solid tumors or lymphomas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additional information on the presentation can be found below and can be accessed at www.esmo.org.

CA-170 Poster Presentation:

Date/Time: Monday, Sept. 11, 9:15 AM — 10:45 AM CEST
Abstract Number: 1141PD
CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in
Presentation Title: pre-clinical models and promotes T cell activation in Phase 1 study